BioSpace News Archive

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is de

Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mas

Monitoring is the regular observation and recording of activities and vitals when animals are under anesthesia and also identifying other disease conditions.

The notable rise in the demand for hereditary genetic testing over the past few years is one of the major factors that is expected to fuel the growth of the global genetic analysis services market in the upcoming decade.

Bone-regeneration techniques, either with autografts or allografts, represent a challenge for reconstructive surgery.

Across the world, rising prevalence of cardiovascular diseases coupled with rising adoption of preventive medicine are fuelling the cardiac ultrasound systems market.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has completed the first three Neovasc Reducer™ (“Reducer”) implants in France.

According to Mortality Due to Cancer 2020: Benchmarking Cancer Mortality in Canada, a new study examining the performance of Canada and its provinces on a number of health indicators, including mortality due to cancer, Canada earns a “B” mark when it comes to overall mortality due to cance

Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face or scalp

− Product and Pipeline Goals Include Execution on Four Commercial Brands, One New NDA Filing, Two Phase 3 Data Readouts, Amongst Other Milestones – – New Clinical Data Presented from Phase 1 Monotherapy Study of ALN-AGT Show Mean Reduction in 24-Hour Systolic Blood Pressure of Over 15 mm Hg – – New Highlighted Programs Include Investigational RNAi Therapeutics for Recurrent Renal Stones, Non-alcoholic Steatohepatitis (NASH),